Is the price fair?
What MTD's price assumes
Mettler Toledo trades at 31.5× earnings against 35.3× for the median Diagnostics & Research name, cheaper than its own group.
31.5
Trailing P/E · Diagnostics & Research median 35.3 · cheaper than the typical name in its group
- Price / sales
- 6.27
Price / sales · as of 2026-Q1
- Free cash flow yield
- 3.7%
Free cash flow yield · Diagnostics & Research median 4.2%
- Growth the price implies
- +9.5%
Growth the price implies · The price pays for +9.5% free cash flow growth a year for a decade; the business has delivered +0.22% a year over the last three.
Details›
- EV / sales2026-Q1
- 6.79
- Healthcare median P/E362 names
- 31.5
- Diagnostics & Research median P/E29 names
- 35.3
- Free cash flow, trailing twelve months
- $864M
- Market capitalisation
- $23.1B
- 3-year revenue growth
- +1.5%
- 3-year free cash flow growth
- +0.22%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $1,493.29 |
| Its own P/E history, median | $1,558.43 |
| Its own P/E history, upper quartile | $1,709.02 |
| 52-week range | $1,025.53 – $1,506.02 |
| Today | $1,398.27 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
Ranks #12 of 29 by Smart Score